BAM
IBRX icon

Barrett Asset Management’s ImmunityBio IBRX Stock Holding History

Barrett Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7,500
Closed -$23K – 380
2018
Q2 		$23K Buy
+7,500
New +$27.8K ﹤0.01% 299

Other funds holding IBRX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Barrett Asset Management's IBRX Position: Q3 2018 in Review

Barrett Asset Management sold out of ImmunityBio (IBRX) in Q3 2018, closing a stake of 7,500 shares — an estimated $23K sold.

Barrett Asset Management first reported a position in IBRX in Q2 2018 and held it in 1 quarter. The position peaked at $23K in Q2 2018. 61 funds tracked by Wall St. Rank hold IBRX as of Q3 2018.

  • Barrett Asset Management reported no remaining ImmunityBio position as of Q3 2018 after selling out during the quarter.
  • Barrett Asset Management sold 7,500 ImmunityBio shares in Q3 2018, an estimated $23K.
  • Barrett Asset Management first reported a position in ImmunityBio in Q2 2018 and held it in 1 quarter.
  • Barrett Asset Management's ImmunityBio position peaked at $23K in Q2 2018.
  • 61 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2018.

Based on Barrett Asset Management's 13F filing for Q3 2018, filed 9 Nov 2018.